Launch OTC NARCAN Nasal Spray
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 8 Aug 2023
- Due
- 30 Sep 2023
- Delivered
- August 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The launch of OTC NARCAN Nasal Spray is still on track for later this summer.”
What we found
Evidence strength A What the grades mean
Emergent BioSolutions successfully launched the over-the-counter NARCAN Nasal Spray in August 2023, which falls within the third quarter and the summer timeframe.
-
A Emergent BioSolutions Inc. 10-Q filed 2023-12-11
“The new OTC product was shipped out to retailers and e-commerce providers nationwide in August of 2023.” ✓ confirmed on the page
-
A Emergent BioSolutions Inc. 10-Q filed 2023-12-11
“Beginning in the third quarter of 2023, the Company launched the over-the-counter NARCAN® (naloxone HCl) Nasal Spray” ✓ confirmed on the page
Market reaction: the shares moved -10.3% against the S&P 500 over the three sessions around the disclosure (8 Dec 2023 to 13 Dec 2023). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Commercial launch
- Indicative materiality
- Medium rules
- Action
- Launch
- Deliverable
- OTC NARCAN Nasal Spray
- In the company’s control
- High
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Emergent BioSolutions Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-EBS-002485 · Corrections policy